Is Gonadorelin FDA approved?

Gonadorelin is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is PT-141 FDA approved?

PT-141 is FDA approved (FDA status current as of 2019-06-21). This regulatory status is provided for research and educational context only.

How is Gonadorelin administered in research settings?

In research settings, Gonadorelin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is PT-141 administered in research settings?

In research settings, PT-141 is typically administered via the subcutaneous or intranasal routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Gonadorelin vs PT-141

Peptide Comparison

Gonadorelin vs PT-141

Name: Gonadorelin vs PT-141 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Reproductive & Hormonal peptides.

Gonadorelin

GnRH

Sexual HealthNot EvaluatedCompoundable

Half-life: ~2-4 minutes

26 providers listed

Full Gonadorelin profile →

PT-141

Bremelanotide

Sexual HealthFDA ApprovedPrescription

Half-life: 2–3 hours

292 providers listed

Full PT-141 profile →

Bottom line

PT-141 is FDA-approved, while Gonadorelin is not evaluated — the clearest structural difference between them.

Quick Verdict

Gonadorelin

Half-life

~2-4 minutes

PT-141

Half-life

2–3 hours

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Gonadorelin
Further along in FDA review	PT-141
Less frequent dosing (longer half-life)	PT-141
Lower typical price per mg	PT-141
More provider options (26 vs 292)	PT-141

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Gonadorelin

PT-141

Mechanism Family

Reproductive & Hormonal

Half-life

~2-4 minutes

2–3 hours

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, intravenous

subcutaneous, intranasal

Availability

Compoundable

Prescription

Providers

26 listed

292 listed

FDA Update

—

Jun 2019

Avail. Notes

Previously FDA-approved as Factrel (NDA 017019). Voluntarily discontinued by manufacturer. Included on the FDA 503B outsourcing-facility bulk-substances list (Category 1), not the 503A pharmacy list. Prescription compounded product.

FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Research Evidence

Gonadorelin

Meta-analysis · 3 key studies · most recent 2026

PT-141

RCT · 5 key studies · most recent 2026

Research Citations

Gonadorelin

Meta-analysis2018 · Fertility and Sterility

Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and fu…

Animal2026 · J Reprod Dev

Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: compariso…

Animal2026 · J Dairy Sci

Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone…

PT-141

RCT2019 · Obstetrics and Gynecology

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Review2026 · Int J Mol Sci

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…

Review2021 · CNS Spectrums

The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal wom…

Review2020 · Ann Pharmacother

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

+1 more

About Gonadorelin

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Research Areas

pulsatile LH and FSH stimulation from the pituitarytesticular function and testosterone production maintenancefertility preservation alongside TRT (FSH pathway intact)hypothalamic-pituitary axis restoration in hypogonadism

About PT-141

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Research Areas

centrally mediated sexual arousal via MC3R and MC4R agonismFDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal womenoff-label use in men for erectile dysfunction and libidonausea and flushing reported in ~40% of users — dose-timing management

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Gonadorelin

Reported (Unverified — Pending Clinical Review)

continuous high-dose (causes receptor downregulation)

No established clinical contraindications

Suggested Monitoring

Total testosteroneLHFSHEstradiol (E2)SHBGProlactin

Standard reproductive endocrinology panels establish HPG axis baseline. LH and FSH confirm pituitary response to gonadorelin; testosterone, E2, and SHBG reflect downstream gonadal output.

PT-141

Absolute Contraindications

Uncontrolled hypertensionKnown cardiovascular diseaseKnown hypersensitivity

Warnings & Cautions

Transient BP increase / HR decrease after dosingNot recommended in patients at high risk for CVDFocal hyperpigmentation with repeated useReduces efficacy of naltrexone-containing products (concurrent use not recommended)Pregnancy — avoid

Source: FDA label

Suggested Monitoring

Blood pressure

FDA prescribing information for bremelanotide identifies transient blood pressure elevation as the primary safety concern. Baseline cardiovascular assessment and BP monitoring are recommended.

Used Together?

PT-141

Oxytocin
Research suggests PT-141 and Oxytocin may produce complementary sexual health effects when combined. PT-141 activates central melanocortin receptors involved in arousal signaling, while oxytocin modulates bonding, reward, and peripheral reproductive pathways.
Antihypertensive medications
Research notes that PT-141 may influence cardiovascular hemodynamics via central melanocortin pathways. Combined use with antihypertensive medications may require monitoring. Consult your prescriber before combining.

Price (per mg)

Gonadorelin

$8.45/mg

$6.90 – $14.95 range

10 vendors

View price index →Find providers →

PT-141

$4.05/mg

$3.22 – $4.50 range

53 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Gonadorelin

26 listed

Browse directory →

Providers offering

PT-141

292 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Reproductive & Hormonal Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Gonadorelin vs PT-141 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/gonadorelin/pt-141

https://peptidebase.io/peptides/compare/gonadorelin/pt-141 Methodology License Download JSON Download CSV